Clinical Trial Update: S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating irinotecan in patients with refractory ovarian epithelial, primary peritoneal, or fallopian tube cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: TERMINATED